Status and phase
Conditions
Treatments
About
TD-1607, administered intravenously as multiple ascending doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject has no clinically significant abnormalities in the results of laboratory evaluations at Screening and Day -1.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
48 participants in 6 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal